Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | INCB081776 |
| Synonyms | |
| Therapy Description |
INCB081776 is a dual inhibitor of Axl and Mer that blocks TAM family kinase signaling, which may results in enhanced anti-tumor immunity (Cancer Res 2018;78(13 Suppl):Abstract nr 3759). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| INCB081776 | INCB-081776 | AXL Inhibitor 30 | INCB081776 is a dual inhibitor of Axl and Mer that blocks TAM family kinase signaling, which may results in enhanced anti-tumor immunity (Cancer Res 2018;78(13 Suppl):Abstract nr 3759). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03522142 | Phase I | INCB081776 INCB081776 + Nivolumab | A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors | Terminated | USA | SWE | NOR | NLD | DNK | 0 |